BMO's Kostas Biliouris: It will be challenging for the FDA to force a market withdrawal for Sarepta
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
International Business Machines Corporation (IBM): Don't Abandon The Stock, Warns Jim Cramer
We recently published . International Business Machines Corporation (NYSE:IBM) is one of the stocks Jim Cramer recently discussed. International Business Machines Corporation (NYSE:IBM) is one of Cramer's favorite technology stocks. Throughout this year, the CNBC TV host has expressed optimism about the firm's CEO and the firm's consistency in winning contracts for its enterprise computing business. International Business Machines Corporation (NYSE:IBM)'s shares fell by 7.6% after the firm's latest earnings report saw software revenue of $7.39 billion miss analyst estimates of $7.43 billion. Cramer discussed the earnings report: 'Most of the news is good this morning, IBM. I still think not as bad, uh, Chipotle we have to talk about. Copyright: believeinme33 / 123RF Stock Photo Previously, he discussed potential future International Business Machines Corporation (NYSE:IBM) share price movement: 'Oh, I like IBM very much. I mentioned Ben Wright earlier. I think that Ben, he's really turned me on to this stock. We did a very positive piece about it. I think it goes, I'm going to say not much higher but creeping higher over time, and that's actually a great place to be. So I like IBM.' While we acknowledge the potential of IBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
CNBC
7 hours ago
- CNBC
‘This market is pricing in perfection,' warns Verdence Capital CIO as tariff deadline looms
The market may be trading around record highs, but the Verdence Capital Advisors CIO is worried trouble is lurking. Megan Horneman, who oversees $4.1 billion in assets under management, thinks there's too much complacency around the Aug. 1 U.S. trade deadline. "This market is pricing in the perfect situation," she told CNBC's "Fast Money" on Monday. In addition to tariff concerns, she lists uncertainty regarding Federal Reserve policy and overbought conditions from a technical perspective as potential issues. "Once we see that [rate cuts] might be priced off the table, coinciding with the fact that we're not quite sure what's going to happen with the tariff perspective, I think you can see a bit of a valuation correction," said Horneman, who's a former Deutsche Bank senior investment strategist. Horneman is particularly concerned that technical levels are signaling overbought conditions in growth stocks — including Big Tech. "These are things that we think might upset the rally that we're seeing here," she said. Despite her short-term caution, Horneman considers herself a long-term bull and views pullbacks as opportunities. She lists international stocks among her top plays on market weakness. "I'd warn that right now, they're expensive from a valuation perspective [but] cheap compared to the U.S.," she said. "They've been underloved for way too long, and I think you're seeing some of that rotation just begin. I think that can continue." To navigate the uncertainty, her key advice to investors right now: Make sure you're allocated appropriately. "Fast Money" trader Guy Adami also sees concerns, citing the number of retail investors driving recent market gains."Just in terms of valuation, things have gotten a tad frothy here," he said on Monday's show. The S&P 500 closed at record highs every day last week. As of Friday's close, the index is 16% over the past three months while the tech-heavy Nasdaq is up 21% over the same period. The Nasdaq is also atDisclaimer
Yahoo
15 hours ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
We recently compiled a list of Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued stocks. It is a leading American biotech company specializing in treatments for serious diseases across ophthalmology, immunology, oncology, and rare conditions. The company is known for integrating genetics and technology into its drug discovery efforts and continues to grow through internal innovation and strategic acquisitions. In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe's assets for $256 million, including its personal genome service, research services, biobank, and associated data. This will expand the business's access to genetic information from 15 million individuals (with 80% consenting to research use), enhancing its existing warehouse of 3 million anonymized samples. The acquisition significantly boosts Regeneron's capabilities in genetics-guided drug development and precision medicine. The vast dataset will help identify new drug targets, refine clinical trial designs, and improve patient stratification. This positions the corporation to lead the integration of real-world genomic data into personalized healthcare. A pharmacist at work in their online pharmacy checking over orders for pharmaceutical products. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) continues to advance its pipeline with FDA priority reviews for Dupixent (bullous pemphigoid) and Linvoseltamab (multiple myeloma), as well as promising late-stage results for EYLEA HD in eye disorders. The firm's focus remains on leveraging data and science to drive innovative, effective therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
